The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Open accessAbstract
T cells in tumors-the so-called tumor infiltrating lymphocytes (TIL) have been studied intensively over the past years. Compelling evidence point to a clinical relevance for high numbers of T cells at the tumor site with CD8 memory T cells as a key denominator for overall survival (OS) in patients with colo-rectal cancer (CRC), and also for others solid cancers. These data goes hand in hand with studies of clonality of TIL showing the T cells among TIL are expanded clonally, and also that tumor specific T cells of CD4 as well as CD8 type are enriched at the tumor site. The tumor microenvironment is hostile to T cell function e.g., due to expression of enzymes that depletes the amino acids tryptophan and arginine, high concentration of tumor secreted lactate, and presence innate cells or regulatory T cells both with suppressive activity. Analyses of the specificity of TILs in melanoma demonstrate that quite few known antigens are in fact recognized by these cultures underscoring patient unique and/or mutated antigens may represent important target for recognition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Renal cell carcinoma is one of the additional tumors considered immunogenic and with proven clinical benefit for immune modulatory treatments such as IL-2 or PD1 and CTLA-4 blockade [16, 28, 49, 109], however tumorinfiltrating lymphocytes has not yet proven feasible for adoptive T cell therapy in this disease.”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 3×
“Moreover, the capacity of the T cells to infiltrate deep into the core of the tumor is fundamental in terms of anti-tumor activity that translate into benefit in survival benefit [36].”
BackgroundResultInfluentialClonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
Feng, H., Shuda, M., Chang, Y., & Moore, P. S. (2008) · Science · doi:10.1126/science.1152586 · Cited by 3,208
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,277
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028
A very high level of crossreactivity is an essential feature of the T-cell receptor
Mason, D. (1998) · Immunology Today · doi:10.1016/s0167-5699(98)01299-7 · Cited by 945
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S. W., Saw, R. P., & Thompson, J. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8539 · Cited by 856
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Cancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 791
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1005 · Cited by 589
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F., Reuter, V. E., Herr, H., Old, L. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611618104 · Cited by 526
Vukmanovic-Stejic, M., Zhang, Y., Cook, J. E., Fletcher, J. M., McQuaid, A., Masters, J. E., Rustin, M. H. A., Taams, L. S., Beverley, P. C. L., Macallan, D. C., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28941 · Cited by 480
Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 456
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432
Radvanyi, L. G., Bernatchez, C., Zhang, M., Fox, P. S., Miller, P., Chacon, J., Wu, R., Lizee, G., Mahoney, S., Alvarado, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1177 · Cited by 427
Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I. E., Kwappenberg, K. M. C., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. M., Kenter, G. G., Fleuren, G. J., Offringa, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3388 · Cited by 414 · cited 1×
“T cell infiltration to cervical cancer with higher CD8/CD4 ratio and higher CD8/Treg ratio is correlated with absence of lymph node metastasis in patients with large early-stage cervical cancer, and even further supported by the presence of a strong systemic anti-vial T cell response [83].”
BackgroundSharma, M. D., Hou, D.-Y., Liu, Y., Koni, P. A., Metz, R., Chandler, P., Mellor, A. L., He, Y., & Munn, D. H. (2009) · Blood · doi:10.1182/blood-2008-12-195354 · Cited by 409
Welters, M. J. P., Kenter, G. G., Piersma, S. J., Vloon, A. P. G., Löwik, M. J. G., Berends-van der Meer, D. M. A., Drijfhout, J. W., Valentijn, A. R. P. M., Wafelman, A. R., Oostendorp, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1880 · Cited by 373
Design and use of conditional MHC class I ligands
Toebes, M., Coccoris, M., Bins, A., Rodenko, B., Gomez, R., Nieuwkoop, N. J., van de Kasteele, W., Rimmelzwaan, G. F., Haanen, J. B. A. G., Ovaa, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1360 · Cited by 347
Meyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
Tissue-based class control: the other side of tolerance
Matzinger, P., & Kamala, T. (2011) · Nature Reviews Immunology · doi:10.1038/nri2940 · Cited by 343
Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma
Kryczek, I., Wei, S., Zhu, G., Myers, L., Mottram, P., Cheng, P., Chen, L., Coukos, G., & Zou, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1866 · Cited by 337
Hadrup, S. R., Bakker, A. H., Shu, C. J., Andersen, R. S., van Veluw, J., Hombrink, P., Castermans, E., thor Straten, P., Blank, C., Haanen, J. B., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1345 · Cited by 306 · cited 1×
“Screening of peptide-specific T-cell responses was conducted by MHCmultimers, generated by peptide exchange from conditional ligand-HLA complexes and combinatorially encoded with different fluorescence molecules to generate unique twocolor codes allowing parallel detection of large numbers of different antigen specifi…”
MethodSelf-citationPaulson, K. G., Iyer, J. G., Tegeder, A. R., Thibodeau, R., Schelter, J., Koba, S., Schrama, D., Simonson, W. T., Lemos, B. D., Byrd, D. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.6308 · Cited by 302
Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma
Donskov, F., & von der Maase, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9594 · Cited by 299
Tumour progression and the nature of cancer
Clark, W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.375 · Cited by 282
Andersen, M. H., Pedersen, L. Ø., Capeller, B., Bröcker, E. B., Becker, J. C., & Straten, P. T. (2001) · PubMed · Cited by 255
Karim, R., Jordanova, E. S., Piersma, S. J., Kenter, G. G., Chen, L., Boer, J. M., Melief, C. J. M., & van der Burg, S. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1652 · Cited by 251
Cho, Y.-A., Yoon, H.-J., Lee, J.-I., Hong, S.-P., & Hong, S.-D. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.08.007 · Cited by 245
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation
Pedroza-Gonzalez, A., Xu, K., Wu, T.-C., Aspord, C., Tindle, S., Marches, F., Gallegos, M., Burton, E. C., Savino, D., Hori, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102131 · Cited by 237
Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+
Sfanos, K. S., Bruno, T. C., Meeker, A. K., De Marzo, A. M., Isaacs, W. B., & Drake, C. G. (2009) · The Prostate · doi:10.1002/pros.21020 · Cited by 233
Zhou, J., Dudley, M. E., Rosenberg, S. A., & Robbins, P. F. (2005) · Journal of Immunotherapy · doi:10.1097/00002371-200501000-00007 · Cited by 225
Overall survival and PD‐L1 expression in metastasized malignant melanoma
Gadiot, J., Hooijkaas, A. I., Kaiser, A. D. M., van Tinteren, H., van Boven, H., & Blank, C. (2011) · Cancer · doi:10.1002/cncr.25747 · Cited by 221
Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A., & Allison, J. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019499 · Cited by 213
Ghebeh, H., Barhoush, E., Tulbah, A., Elkum, N., Al-Tweigeri, T., & Dermime, S. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-57 · Cited by 211
Pilon-Thomas, S., Kuhn, L., Ellwanger, S., Janssen, W., Royster, E., Marzban, S., Kudchadkar, R., Zager, J., Gibney, G., Sondak, V. K., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31826e8f5f · Cited by 198
Schmidt, H., Suciu, S., Punt, C. J. A., Gore, M., Kruit, W., Patel, P., Lienard, D., von der Maase, H., Eggermont, A. M. M., & Keilholz, U. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0274 · Cited by 190
TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., van Rooij, N., Linnemann, C., van Buuren, M. M., Urbanus, J. H. M., et al. (2012) · OncoImmunology · doi:10.4161/onci.18851 · Cited by 178
Self-citationEllebaek, E., Iversen, T. Z., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L. R., Andersen, R. S., Hadrup, S. R., Andersen, M. H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-169 · Cited by 172
Self-citationPredominant Expression of T Cell Receptor V α 7 in Tumor-Infiltrating Lymphocytes of Uveal Melanoma
Nitta, T., Oksenberg, J. R., Rao, N. A., & Steinman, L. (1990) · Science · doi:10.1126/science.2382141 · Cited by 167
Immunotherapy for Ovarian Cancer: What's Next?
Kandalaft, L. E., Powell, D. J., Singh, N., & Coukos, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2369 · Cited by 164
HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses
Lepique, A. P., Daghastanli, K. R. P., Cuccovia, I. M., & Villa, L. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0489 · Cited by 159
Iyer, J. G., Afanasiev, O. K., McClurkan, C. L., Paulson, K. G., Nagase, K., Jing, L., Marshak, J. O., Dong, L., Carter, J., Lai, I. P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1513 · Cited by 159
Dissection of T-cell Antigen Specificity in Human Melanoma
Andersen, R. S., Thrue, C. A., Junker, N., Lyngaa, R., Donia, M., Ellebæk, E., Svane, I. M., Schumacher, T. N., thor Straten, P., & Hadrup, S. R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2614 · Cited by 158
Self-citationFerradini, L., Mackensen, A., Genevée, C., Bosq, J., Duvillard, P., Avril, M.-F., & Hercend, T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116278 · Cited by 150
Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
Witkiewicz, A. K., Costantino, C. L., Metz, R. A., Muller, A. J., Prendergast, G. C., Yeo, C. J., & Brody, J. R. (2009) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.12.018 · Cited by 141
Tryptophan hydroxylase-1 regulates immune tolerance and inflammation
Nowak, E. C., de Vries, V. C., Wasiuk, A., Ahonen, C. L., Bennett, K. A., Mercier, I. L., Ha, D.-G., & Noelle, R. J. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120408 · Cited by 132
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Sørensen, R. B., Hadrup, S. R., Svane, I. M., Hjortsø, M. C., Straten, P. T., & Andersen, M. H. (2010) · Blood · doi:10.1182/blood-2010-06-288498 · Cited by 131
Self-citationCoulie, P. G., Somville, M., Lehmann, F. F., Hainaut, P., Brasseur, F., Devos, R., & Boon, T. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500220 · Cited by 130
Lee, K.-H., Panelli, M. C., Kim, C. J., Riker, A. I., Bettinotti, M. P., Roden, M. M., Fetsch, P. A., Abati, A. D., Rosenberg, S. A., & Marincola, F. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4183 · Cited by 124
Besser, M. J., Shapira‐Frommer, R., Treves, A. J., Zippel, D. B., Itzhaki, O., Schallmach, E., Kubi, A., Shalmon, B., Hardan, I., Catane, R., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819c8bda · Cited by 121
Regulators of apoptosis: suitable targets for immune therapy of cancer
Andersen, M. H., Becker, J. C., & Straten, P. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1717 · Cited by 115
Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes
Friedman, K. M., Prieto, P. A., Devillier, L., Gross, C. A., Yang, J. C., Wunderlich, J. R., Rosenberg, S. A., & Dudley, M. E. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825898c5 · Cited by 110
Liu, H., Liu, L., Liu, K., Bizargity, P., Hancock, W. W., & Visner, G. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900408 · Cited by 94
Attig, S., Hennenlotter, J., Pawelec, G., Klein, G., Koch, S. D., Pircher, H., Feyerabend, S., Wernet, D., Stenzl, A., Rammensee, H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0852 · Cited by 90
Valmori, D., Dutoit, V., Líénard, D., Lejeune, F. J., Speiser, D. E., Rimoldi, D., Cerundolo, V., Dietrich, P., Cerottini, J., & Romero, P. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.533 · Cited by 89
Jaafar, F., Righi, E., Lindstrom, V., Linton, C. E., Nohadani, M., Noorden, S. V., Lloyd, T., Poznansky, J., Stamp, G., Dina, R. E., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090295 · Cited by 87
Robbins, P. F., El‐Gamil, M., Li, Y. F., Zeng, G., Dudley, M. E., & Rosenberg, S. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.6036 · Cited by 86
Identification of heme oxygenase-1–specific regulatory CD8+ T cells in cancer patients
Andersen, M. H., Sørensen, R. B., Brimnes, M. K., Svane, I. M., Becker, J. C., & Straten, P. T. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38739 · Cited by 80
Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration
Andersen, M. H., Gehl, J., Hadrup, S. R., Pedersen, L. Ø., Becker, J. C., Geertsen, P. F., & Straten, P. T. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.009 · Cited by 80
Self-citationWang, Q. J., Hanada, K., Robbins, P. F., Li, Y. F., & Yang, J. C.-H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0588 · Cited by 76
Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases
Panelli, M. C., Riker, A. I., Kammula, U. S., Wang, E., Lee, K.-H., Rosenberg, S. A., & Marincola, F. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.495 · Cited by 75
Méndez, R., Aptsiauri, N., Campo, A. D., Maleno, I., Cabrera, T., Ruiz‐Cabello, F., Garrido, F., & Garcia-Lora, A. M. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0701-z · Cited by 70
The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
Sørensen, R. B., Berge-Hansen, L., Junker, N., Hansen, C. A., Hadrup, S. R., Schumacher, T. N., Svane, I. M., Becker, J. C., Straten, P. T., & Andersen, M. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006910 · Cited by 69
Self-citationStraten, P. T., Guldberg, P., Grønbæk, K., Hansen, M. R., Kirkin, A. F., Seremet, T., Zeuthen, J., & Becker, J. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.443 · Cited by 66
Panelli, M. C., Bettinotti, M. P., Lally, K. M., Ohnmacht, G. A., Li, Y., Robbins, P. F., Riker, A. I., Rosenberg, S. A., & Marincola, F. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4382 · Cited by 59
Straten, P. T., Becker, J. X. F. R. C., Guldberg, P., & Zeuthen, J. (1999) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050591 · Cited by 58
Dadmarz, R., Sgagias, M. K., Rosenberg, S. A., & Schwartzentruber, D. J. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01517229 · Cited by 57
Dadmarz, R., Ordoubadi, A., Mixon, A., Thompson, C. O., Barracchini, K. C., Hijazi, Y. M., Steller, M. A., Rosenberg, S. A., & Schwartzentruber, D. J. (1996) · PubMed · Cited by 54
Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
Sørensen, R. B., Køllgaard, T., Andersen, R. S., van den Berg, J. H., Svane, I. M., Straten, P. T., & Andersen, M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3403 · Cited by 53
Poschke, I. C., de Boniface, J., Mao, Y., & Kiessling, R. W. (2011) · International Journal of Cancer · doi:10.1002/ijc.27410 · Cited by 53
Use of viral promoters in mammalian cell-based bioassays: How reliable?
Betrabet, S. S., Choudhuri, J., & Gill‐Sharma, M. K. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-1 · Cited by 53
Regulation of T-cell functions by l-lactate
Dröge, W., Roth, S., Altmann, A., & Mihm, S. (1987) · Cellular Immunology · doi:10.1016/0008-8749(87)90223-1 · Cited by 49
Donia, M., Hansen, M., Sendrup, S. L., Iversen, T. Z., Ellebæk, E., Andersen, M. H., Straten, P. T., & Svane, I. M. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.336 · Cited by 46
Self-citationJunker, N., Andersen, M. H., Wenandy, L., Dombernowsky, S. L., Kiss, K., Sørensen, C. H., Therkildsen, M. H., von Buchwald, C., Andersen, E., Straten, P. T., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2011.563291 · Cited by 41
Habibi, D., Jalili, R. B., Forouzandeh, F., Ong, C. J., & Ghahary, A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22220 · Cited by 23
Straten, P. T., Schrama, D., Andersen, M. H., & Becker, J. C. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-11 · Cited by 18
Cited by
Macrophage Polarization States in the Tumor Microenvironment
Boutilier, A. J., & Elsawa, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136995 · Cited by 1,631
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
“When the PD-1/PD-L1 checkpoint axis is blocked, there is often an increase in effector T-cell function and tumor infiltration (19, 20).”
Backgroundde Ruiter, E. J., Ooft, M. L., Devriese, L. A., & Willems, S. M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356148 · Cited by 340
Repurposing metformin for cancer treatment: current clinical studies
Chae, Y. K., Arya, A., Malecek, M.-K., Shin, D. S., Carneiro, B., Chandra, S., Kaplan, J., Kalyan, A., Altman, J. K., Platanias, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8194 · Cited by 316
Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches
Brodt, P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0460 · Cited by 301
Metadata
- Authors
- Hadrup, S., Donia, M., & thor Straten, P.
- Venue
- Cancer Microenvironment
- Published
- 2012-12-16
- Volume
- 6
- Issue
- 2
- Pages
- 123-133
- ISSN
- 1875-2284 (ISSN-L)
- 1875-2292
- OpenAlex
- W2053725511
- Cited by
- 310
- References
- 105
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.